Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
How do inflammatory pathways strain the cardiovascular system? Dr. Mark Gorelik provided insights into the inflammatory processes that influence heart recovery after myocardial infarction, Kawasaki disease, multi-system inflammatory syndrome in children and more.
During the ACR Convergence 2021 Review Course, Joan Bathon, MD, discussed cardiovascular manifestations of autoimmune diseases, including rheumatoid arthritis.
Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.
In a controlled, large-cohort, longitudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1 This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…
Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population. Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research…
NEW YORK (Reuters Health)—Dual energy computed tomography (DECT) can differentiate cardiovascular monosodium urate (MSU) deposits from calcium deposits in patients with gout, potentially identifying those at risk of heart disease, researchers say. Sylvia Strobl, MD, of Medical University Innsbruck and colleagues analyzed calcium scores and MSU deposits in 59 patients with gout (mean age: 59;…
ZURICH (Reuters)—The U.S. Food and Drug Administration (FDA) has rejected Novartis’s bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, according to the Swiss drugmaker. The company received an FDA letter turning down its bid to make canakinumab a targeted therapy for those…